Corinne Johnson
Stock Analyst at Goldman Sachs
(4.35)
# 1,274
Out of 4,531 analysts
245
Total ratings
54.8%
Success rate
11.9%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintained: Hold | $33 → $37 | $33.77 | +9.56% | 23 | Jul 16, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 | $22.80 | +49.12% | 8 | Jul 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $20 → $23 | $17.75 | +29.58% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Maintained: Sell | $56 → $57 | $77.81 | -26.74% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $158 → $159 | $106.60 | +49.16% | 31 | Jun 14, 2026 | |
| TGTX TG Therapeutics | Maintained: Hold | $41 | $54.87 | -25.28% | 21 | Jun 3, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Hold | $35 → $36 | $36.01 | -0.03% | 11 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $170.88 | +24.65% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $10.73 | +39.79% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Maintained: Buy | $27 → $25 | $15.44 | +61.92% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2.5 | $2.87 | -12.89% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $40.26 | -20.52% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $41 | $34.51 | +18.81% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $102 → $101 | $48.48 | +108.33% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.44 | -30.56% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $82 | $71.85 | +14.13% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $62.92 | -49.19% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $33.19 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.65 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.50 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $7.22 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.8874 | n/a | 14 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.68 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $1.55 | n/a | 1 | Sep 14, 2021 |
Harmony Biosciences Holdings
Jul 16, 2026
Maintained: Hold
Price Target: $33 → $37
Current: $33.77
Upside: +9.56%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $34
Current: $22.80
Upside: +49.12%
Amylyx Pharmaceuticals
Jun 18, 2026
Maintained: Buy
Price Target: $20 → $23
Current: $17.75
Upside: +29.58%
Halozyme Therapeutics
Jun 14, 2026
Maintained: Sell
Price Target: $56 → $57
Current: $77.81
Upside: -26.74%
Rhythm Pharmaceuticals
Jun 14, 2026
Maintained: Buy
Price Target: $158 → $159
Current: $106.60
Upside: +49.16%
TG Therapeutics
Jun 3, 2026
Maintained: Hold
Price Target: $41
Current: $54.87
Upside: -25.28%
IDEAYA Biosciences
Jun 3, 2026
Maintained: Hold
Price Target: $35 → $36
Current: $36.01
Upside: -0.03%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $170.88
Upside: +24.65%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $10.73
Upside: +39.79%
Biohaven
May 28, 2026
Maintained: Buy
Price Target: $27 → $25
Current: $15.44
Upside: +61.92%
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $2.87
Upside: -12.89%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $40.26
Upside: -20.52%
Apr 15, 2026
Maintained: Buy
Price Target: $38 → $41
Current: $34.51
Upside: +18.81%
Mar 16, 2026
Maintained: Buy
Price Target: $102 → $101
Current: $48.48
Upside: +108.33%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.44
Upside: -30.56%
Jan 12, 2026
Maintained: Buy
Price Target: $56 → $82
Current: $71.85
Upside: +14.13%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $62.92
Upside: -49.19%
Jul 18, 2025
Maintained: Buy
Price Target: n/a
Current: $33.19
Upside: n/a
Jul 31, 2024
Maintained: Buy
Price Target: n/a
Current: $3.65
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.50
Upside: n/a
Jun 18, 2024
Maintained: Hold
Price Target: n/a
Current: $7.22
Upside: n/a
Nov 14, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.8874
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $5.68
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $1.55
Upside: n/a